Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial

Considering the anti‐inflammatory properties of curcumin, the present study was designed to investigate the effect of nano‐curcumin on respiratory indices and interleukin‐6 (IL‐6) levels in severe chronic obstructive pulmonary disease (COPD) patients as a common pulmonary disease causing restricted airflow and breathing problems. In the current double‐blind placebo‐controlled randomized clinical trial study, 60 patients with stages 3 and 4 COPD were randomly assigned into 80 mg nano‐curcumin (n = 30) and placebo groups (n = 30) for 3 months. The effect of nano‐curcumin on pulmonary function was evaluated by the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC) ratio. IL‐6 serum level, blood pressure, and anthropometric indices were also measured. Nano‐curcumin supplementation led to a significant decrease in IL‐6 level (p